Deutetrabenazine in Tics Associated with Tourette Syndrome

Tremor and Other Hyperkinetic Movements

Volumn 6, Issue , 2016, Pages

  Jankovic, Joseph ^a   Jimenez Shahed, Joohi ^a   Budman, Cathy ^b   Coffey, Barbara ^c   Murphy, Tanya ^d   Shprecher, David ^e,f   Stamler, David ^g  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e SUN HEALTH RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g wholly owned subsidiary of Teva Pharmaceutical Industries   (United States)

Author keywords

Deutetrabenazine; SD 809; Tics; Tourette syndrome; VMAT2

Indexed keywords

DEUTETRABENAZINE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT HYPERACTIVITY DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COLUMBIA SUICIDE SEVERITY RATING SCALE; DIARRHEA; DISEASE SEVERITY; DISEASE SEVERITY ASSESSMENT; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FATIGUE; GENOTYPE; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HUMAN; HYPERHIDROSIS; IRRITABILITY; MENTAL DISEASE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; QT INTERVAL; RHINOPHARYNGITIS; SCHOOL CHILD; SOMNOLENCE; SUICIDAL BEHAVIOR; TIC; TOTAL TIC SEVERITY SCORE; YALE BROWN OBSESSIVE COMPULSIVE SCALE; YALE GLOBAL TIC SEVERITY SCALE; YOUNG ADULT;

EID: 85125187573     PISSN: None     EISSN: 21608288     Source Type: Journal    
DOI: 10.5334/TOHM.287     Document Type: Article

References (32)

1. Thenganatt MA, Jankovic J. Recent advances in understanding and managing Tourette syndrome. F1000Research 2016;5:152. doi: 10.12688/f1000research.7424.1.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing. 2013.
3. Gilbert DL, Jankovic J. Pharmacological treatment of Tourette syndrome. J Obsessive Compuls Relat Disord 2014;3:407–414. doi: 10.1016/j.jocrd.2014. 04.006.
4. Jankovic J. Therapeutic developments for tics and myoclonus. Mov Disord 2015;30:1566–1573. doi: 10.1002/mds.26414.
5. Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J. Deep brain stimulation for Tourette syndrome: target selection. Stereotact Funct Neurosurg 2012;90:213–224. doi: 10.1159/000337776.
6. Kefalopoulou Z, Zrinzo L, Jahanshahi M, et al. Bilateral globus palli-dus stimulation for severe Tourette’s syndrome: a double-blind, randomised crossover trial. Lancet Neurol 2015; 14: 595–605. doi: 10.1016/S1474-4422(15)00008-3.
7. Jain S, Greene PE, Frucht SJ. Tetrabenazine treatment of pediatric hyperkinetic disorders. Mov Disord 2006;21:1966–1971. doi: 10.1002/mds.21063.
8. Kenney C, Hunter C, N M, Jankovic J. Tetrabenazine in the treatment of Tourette syndrome. J Pediatric Neurol 2007;5:9–13.
9. Porta M, Sassi M, Cavallazzi M, Fornari M, Brambilla A, Servello D. Tourette’s syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig 2008;28:443. doi: 10.2165/00044011-200828070-00006.
10. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358–362. doi: 10.1212/WNL.48.2.358.
11. Burke RE, Reches A, Traub MM, Ilson J, Swash M, Fahn S. Tetrabenazine induces acute dystonic reactions. Ann Neurol 1985;17:200–202. doi: 10.1002/ana.410170217.
12. Janik P, Figura M. Tetrabenazine-induced oculogyric crisis—a rare complication in the treatment of Gilles de la Tourette Syndrome. Neuropsychiatr Dis Treat 2016;12:497–499. doi: 10.2147/NDT.S98694.
13. Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord 2013; 28:210–215. doi: 10.1002/mds.25278.
14. Howland RH. Deuterated drugs. J Psychosoc Nurs Ment Health Serv 2015; 53:13–16.
15. Stamler D, Bradbury M, Brown F. The pharmacokinetics and safety of deuterated-tetrabenazine. Neurology 2013;80:P07.210.
16. Tetrabenazine Medication Guide. Washington DC: Prestwick Pharma-ceuticals; 2008. http://www.xenazineusa.com/HCP/PrescribingXenazine.
17. Huntington Study Group, Frank S, Testa CM, Stamler D, et al. Effect of Deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA 2016 5;316:40–50. doi: 10.1001/jama. 2016.8655.
18. Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989;28:566–573. doi: 10.1097/00004583-198907000-00015.
19. Leckman JF, Towbin KE, Ort SI, et al. Clinical assessment of tic disorder severity. In: Cohen DJ, editor. Tourette’s syndrome and tic disorders. New York, NY: John Wiley & Sons; 1988. p 550–578.
20. Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther 2009;17:163–170. doi: 10.1179/jmt.2009.17.3.163.
21. Jeon S, Walkup JT, Woods DW, et al. Detecting a clinically meaningful change in tic severity in Tourette syndrome: a comparison of three methods. Contemp Clin Trials 2013;36:414–420. doi: 10.1016/j.cct.2013.08.012.
22. Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 2011;26:147–152. doi: 10.1002/mds.23402.
23. Waln O, Jankovic J. An update on tardive dyskinesia: from phenom-enology to treatment. Tremor Other Hyperkinet Mov 2013;3. doi: 10.7916/D88P5Z71.
24. Vijayakumar D, Jankovic J. Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs 2016;76:779–787. doi: 10.1007/s40265-016-0568-1.
25. Muller-Vahl KR, Kruger D. Does Tourette syndrome prevent tardive dyskinesia? Movement Disord 2011;26:2442–2444. doi: 10.1002/mds.23894.
26. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother 2011;11: 1509–1523. doi: 10.1586/ern.11.149.
27. Müller T. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs 2015;24:737–742. doi: 10.1517/13543784.2015.1029573.
28. O’Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord 2015;30: 1681–1687. doi: 10.1002/mds.26330.
29. Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord 2014;29:126–130. doi: 10.1002/mds.25692.
30. Jankovic J, Jimenez-Shahed J, Brown LW. A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2010;81:70–73. doi: 10.1136/jnnp.2009.185348.
31. Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry 2013;74:e772–780. doi: 10.4088/JCP. 12m08189.
32. Gunduz A, Okun MS. A review and update on Tourette syndrome: where is the field headed? Curr Neurol Neurosci Rep 2016;16:37. doi: 10.1007/s11910-016-0633-x.